CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

doi:10.1002/bdd.2135

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Biopharmaceutics & drug disposition - 1 Jun 2018

Quiñones-Lombraña Adolfo, Li Nasi, Del Solar Virginia, Atilla-Gokcumen G Ekin, Blanco Javier G

Abstract excerpt

Loxoprofen is an anti-inflammatory drug that requires bioactivation into the trans-OH metabolite to exert pharmacological activity. Evidence suggests that carbonyl reductase 1 (CBR1) is important during the bioactivation of loxoprofen. This study examined the impact of the functional single nucleotide polymorphism CBR1 rs9024 on the bioactivation of loxoprofen in a collection of human liver samples. The synthesis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alcohol Oxidoreductases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Inflammatory Agents, Non-Steroidal

Share to Cell Line, Tumor

Share to Gene Expression Regulation, Enzymologic

Share to Liver

Share to Phenylpropionates

Share to Polymorphism, Single Nucleotide

Share to RNA, Messenger

Source

Open in PubMed Open full text

Identifiers

PMID: 29851133
DOI: 10.1002/bdd.2135
PMCID: PMC6078805

Genes

CBR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.PMID 29851133Read ↗

Human carbonyl reductase 1 participating in intestinal first-pass drug metabolism is inhibited by fatty acids and acyl-CoAs.Semantic proximity Read ↗

Pharmacogenetics of human carbonyl reductase 1 (CBR1) in livers from black and white donors.Semantic proximity Read ↗

Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases.Semantic proximity Read ↗

A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.Semantic proximity Read ↗

The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation.Semantic proximity Read ↗

Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes.Semantic proximity Read ↗

Challenges and Opportunities with Non-CYP Enzymes Aldehyde Oxidase, Carboxylesterase, and UDP-Glucuronosyltransferase: Focus on Reaction Phenotyping and Prediction of Human Clearance.Semantic proximity Read ↗

In Vitro Evaluation of the Reductase Activities of Human AKR1C3 Allelic Variants.Semantic proximity Read ↗

Identification of the promoter of human carbonyl reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic CBR3 mRNA expression.Semantic proximity Read ↗

The Impact of Carboxylesterases in Drug Metabolism and PharmacokineticsSemantic proximity Read ↗

Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics.Semantic proximity Read ↗

Carbonyl reductase 1 expression influences daunorubicin metabolism in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.